BRIEF-Eli Lilly Issues Warning About Potential Safety Risks Of Tirzepatide Compounded With Vitamin B12

Reuters03-12

March 12 (Reuters) - Eli Lilly and Co LLY.N:

AN OPEN LETTER FROM ELI LILLY AND COMPANY WARNING OF POTENTIAL PATIENT SAFETY RISKS ASSOCIATED WITH TIRZEPATIDE COMPOUNDED WITH VITAMIN B12
ELI LILLY: ISSUING A PUBLIC WARNING ABOUT POTENTIAL SAFETY RISKS ASSOCIATED WITH COMPOUNDED TIRZEPATIDE MIXED WITH VITAMIN B12
ELI LILLY - TESTING UNCOVERED SIGNIFICANT LEVELS OF AN IMPURITY THAT RESULTS FROM A CHEMICAL REACTION BETWEEN TIRZEPATIDE AND B12.
ELI LILLY: POTENTIAL FOR DANGEROUS INTERACTIONS BETWEEN TIRZEPATIDE COMPOUNDED WITH OTHER ADDITIVES REMAINS UNKNOWN
ELI LILLY: HAS NOTIFIED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ABOUT THESE FINDINGS
ELI LILLY: URGE FDA TO CONTINUE TAKING ACTION AGAINST UNLAWFUL MASS COMPOUNDING OF TIRZEPATIDE THAT PUTS THE AMERICAN PUBLIC AT RISK- WEBSITE
LILLY: CONTINUE TO FIND OTHER CRITICAL SAFETY ISSUES IN COMPOUNDED TIRZEPATIDE KNOCKOFFS, INCLUDING BACTERIAL CONTAMINATION, HIGH ENDOTOXIN LEVELS
ELI LILLY: URGE FDA TO CONTINUE TAKING ACTION, INCLUDING BY REQUESTING RECALL OF ALL COMPOUNDED TIRZEPATIDE COMBINED WITH UNTESTED ADDITIVES LIKE B12

Further company coverage: LLY.N

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618041184?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 16:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618041184","market":"us","top_or_hot":-1,"title":"BRIEF-Eli Lilly Issues Warning About Potential Safety Risks Of Tirzepatide Compounded With Vitamin B12","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Eli Lilly Issues Warning About Potential Safety Risks Of Tirzepatide Compounded With Vitamin B12</title></head><body><p><span>March 12 (Reuters)</span><span> - </span>Eli Lilly and Co <span>LLY.N</span>:</p><ul><li><p>AN OPEN LETTER FROM ELI LILLY AND COMPANY WARNING OF POTENTIAL PATIENT SAFETY RISKS ASSOCIATED WITH TIRZEPATIDE COMPOUNDED WITH VITAMIN B12</p></li><li><p>ELI LILLY: ISSUING A PUBLIC WARNING ABOUT POTENTIAL SAFETY RISKS ASSOCIATED WITH COMPOUNDED TIRZEPATIDE MIXED WITH VITAMIN B12</p></li><li><p>ELI LILLY -  TESTING UNCOVERED SIGNIFICANT LEVELS OF AN IMPURITY THAT RESULTS FROM A CHEMICAL REACTION BETWEEN TIRZEPATIDE AND B12.</p></li><li><p>ELI LILLY: POTENTIAL FOR DANGEROUS INTERACTIONS BETWEEN TIRZEPATIDE COMPOUNDED WITH OTHER ADDITIVES REMAINS UNKNOWN</p></li><li><p>ELI LILLY:  HAS NOTIFIED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ABOUT THESE FINDINGS</p></li><li><p>ELI LILLY: URGE FDA TO CONTINUE TAKING ACTION AGAINST UNLAWFUL MASS COMPOUNDING OF TIRZEPATIDE THAT PUTS THE AMERICAN PUBLIC AT RISK- WEBSITE</p></li><li><p>LILLY: CONTINUE TO FIND OTHER CRITICAL SAFETY ISSUES IN COMPOUNDED TIRZEPATIDE KNOCKOFFS, INCLUDING BACTERIAL CONTAMINATION, HIGH ENDOTOXIN LEVELS</p></li><li><p>ELI LILLY: URGE FDA TO CONTINUE TAKING ACTION, INCLUDING BY REQUESTING RECALL OF ALL COMPOUNDED TIRZEPATIDE COMBINED WITH UNTESTED ADDITIVES LIKE B12</p></li></ul><p>Further company coverage: <span>LLY.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Eli Lilly Issues Warning About Potential Safety Risks Of Tirzepatide Compounded With Vitamin B12</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Eli Lilly Issues Warning About Potential Safety Risks Of Tirzepatide Compounded With Vitamin B12\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 16:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Eli Lilly Issues Warning About Potential Safety Risks Of Tirzepatide Compounded With Vitamin B12</title></head><body><p><span>March 12 (Reuters)</span><span> - </span>Eli Lilly and Co <span>LLY.N</span>:</p><ul><li><p>AN OPEN LETTER FROM ELI LILLY AND COMPANY WARNING OF POTENTIAL PATIENT SAFETY RISKS ASSOCIATED WITH TIRZEPATIDE COMPOUNDED WITH VITAMIN B12</p></li><li><p>ELI LILLY: ISSUING A PUBLIC WARNING ABOUT POTENTIAL SAFETY RISKS ASSOCIATED WITH COMPOUNDED TIRZEPATIDE MIXED WITH VITAMIN B12</p></li><li><p>ELI LILLY -  TESTING UNCOVERED SIGNIFICANT LEVELS OF AN IMPURITY THAT RESULTS FROM A CHEMICAL REACTION BETWEEN TIRZEPATIDE AND B12.</p></li><li><p>ELI LILLY: POTENTIAL FOR DANGEROUS INTERACTIONS BETWEEN TIRZEPATIDE COMPOUNDED WITH OTHER ADDITIVES REMAINS UNKNOWN</p></li><li><p>ELI LILLY:  HAS NOTIFIED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ABOUT THESE FINDINGS</p></li><li><p>ELI LILLY: URGE FDA TO CONTINUE TAKING ACTION AGAINST UNLAWFUL MASS COMPOUNDING OF TIRZEPATIDE THAT PUTS THE AMERICAN PUBLIC AT RISK- WEBSITE</p></li><li><p>LILLY: CONTINUE TO FIND OTHER CRITICAL SAFETY ISSUES IN COMPOUNDED TIRZEPATIDE KNOCKOFFS, INCLUDING BACTERIAL CONTAMINATION, HIGH ENDOTOXIN LEVELS</p></li><li><p>ELI LILLY: URGE FDA TO CONTINUE TAKING ACTION, INCLUDING BY REQUESTING RECALL OF ALL COMPOUNDED TIRZEPATIDE COMBINED WITH UNTESTED ADDITIVES LIKE B12</p></li></ul><p>Further company coverage: <span>LLY.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0097036916.USD","symbol_name":"贝莱德美国增长A2 USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nFWN40001L:1","article_id":"2618041184","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618041184","pubTimestamp":1773305395,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Eli Lilly Issues Warning About Potential Safety Risks Of Tirzepatide Compounded With Vitamin B12March 12  - Eli Lilly and Co LLY.N:AN OPEN LETTER FROM ELI LILLY AND COMPANY WARNING OF POTENTIAL PATIENT SAFETY RISKS ASSOCIATED WITH TIRZEPATIDE COMPOUNDED WITH VITAMIN B12ELI LILLY: ISSUING A PUBLIC WARNING ABOUT POTENTIAL SAFETY RISKS ASSOCIATED WITH COMPOUNDED TIRZEPATIDE MIXED WITH VITAMIN B12ELI LILLY -  TESTING UNCOVERED SIGNIFICANT LEVELS OF AN IMPURITY THAT RESULTS FROM A CHEMICAL REACTION BETWEEN TIRZEPATIDE AND B12.ELI LILLY: POTENTIAL FOR DANGEROUS INTERACTIONS BETWEEN TIRZEPATIDE COMPOUNDED WITH OTHER ADDITIVES REMAINS UNKNOWNELI LILLY:  HAS NOTIFIED THE U.S. FOOD AND DRUG ADMINISTRATION  ABOUT THESE FINDINGSELI LILLY: URGE FDA TO CONTINUE TAKING ACTION AGAINST UNLAWFUL MASS COMPOUNDING OF TIRZEPATIDE THAT PUTS THE AMERICAN PUBLIC AT RISK- WEBSITELILLY: CONTINUE TO FIND OTHER CRITICAL SAFETY ISSUES IN COMPOUNDED TIRZEPATIDE KNOCKOFFS, INCLUDING BACTERIAL CONTAMINATION, HI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0097036916.USD":"贝莱德美国增长A2 USD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","BK4581":"高盛持仓","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE00B775H168.HKD":"JANUS HENDERSON BALANCED \"A5M\" (HKD) INC","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","BK4534":"瑞士信贷持仓","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC","BK4516":"特朗普概念","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","SGXZ81514606.USD":"大华环球创新基金A Acc USD","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LLII":"REX LLY Growth & Income ETF","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LLYX":"2倍做多LLY ETF-Defiance","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LLYZ":"2倍做空LLY ETF-Defiance","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LU0882574055.USD":"富达全球健康医疗A ACC","BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","IE0001KFT4U8.USD":"FTGF CLEARBRIDGE GLOBAL GROWTH LEADERS \"A\" (USD) INC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LLY":"礼来","LU0210536198.USD":"JPM US GROWTH \"A\" ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1145028129.USD":"ALLIANZ INCOME AND GROWTH \"AQ\" (USD) INC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2896262040.SGD":"JPM US GROWTH FUND \"A\" (SGD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2756315318.SGD":"ALLIANZ INCOME AND GROWTH \"AMG\" (SGDHDG) INC A","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","BK4588":"碎股","LU1548497426.USD":"安联环球人工智能AT Acc","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU0964807845.USD":"ALLIANZ INCOME & GROWTH \"A\" (USD) INC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4599":"减肥药","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2023250330.USD":"ALLIANZ INCOME AND GROWTH \"AMG\" (USD) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU0079474960.USD":"联博美国增长基金A","LU0882574139.USD":"富达环球消费行业基金A ACC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","SG9999015978.USD":"利安颠覆性创新基金A","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1629891620.HKD":"ALLIANZ INCOME AND GROWTH \"AMG2\" (H2-HKD) INC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2168564495.EUR":"AZ ALLOCATION - TREND \"AI\" (EUR) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2168564222.USD":"AZ ALLOCATION - TREND \"AAZ\" (USDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","ELIL":"2倍做多LLY ETF-Direxion","LU0238689110.USD":"贝莱德环球动力股票基金","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2063271972.USD":"富兰克林创新领域基金","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","ELIS":"1倍做空LLY ETF-Direxion","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","LU2168563687.JPY":"AZ ALLOCATION - TREND \"AAZ\" (JPYHDG) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2168564149.EUR":"AZ ALLOCATION - TREND \"BAZ\" (EUR) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0122379950.USD":"贝莱德世界健康科学A2","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC"},"translate_title":"简报-礼来就替泽帕肽与维生素B12复合的潜在安全风险发出警告","themeId":"911d01174da467501a9861f646959e38","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1.98,"LLII":0.6,"LLYZ":0.6,"ELIS":0.6,"LLYX":0.6,"ELIL":0.6},"content_text":"BRIEF-Eli Lilly Issues Warning About Potential Safety Risks Of Tirzepatide Compounded With Vitamin B12March 12 (Reuters) - Eli Lilly and Co LLY.N:AN OPEN LETTER FROM ELI LILLY AND COMPANY WARNING OF POTENTIAL PATIENT SAFETY RISKS ASSOCIATED WITH TIRZEPATIDE COMPOUNDED WITH VITAMIN B12ELI LILLY: ISSUING A PUBLIC WARNING ABOUT POTENTIAL SAFETY RISKS ASSOCIATED WITH COMPOUNDED TIRZEPATIDE MIXED WITH VITAMIN B12ELI LILLY -  TESTING UNCOVERED SIGNIFICANT LEVELS OF AN IMPURITY THAT RESULTS FROM A CHEMICAL REACTION BETWEEN TIRZEPATIDE AND B12.ELI LILLY: POTENTIAL FOR DANGEROUS INTERACTIONS BETWEEN TIRZEPATIDE COMPOUNDED WITH OTHER ADDITIVES REMAINS UNKNOWNELI LILLY:  HAS NOTIFIED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ABOUT THESE FINDINGSELI LILLY: URGE FDA TO CONTINUE TAKING ACTION AGAINST UNLAWFUL MASS COMPOUNDING OF TIRZEPATIDE THAT PUTS THE AMERICAN PUBLIC AT RISK- WEBSITELILLY: CONTINUE TO FIND OTHER CRITICAL SAFETY ISSUES IN COMPOUNDED TIRZEPATIDE KNOCKOFFS, INCLUDING BACTERIAL CONTAMINATION, HIGH ENDOTOXIN LEVELSELI LILLY: URGE FDA TO CONTINUE TAKING ACTION, INCLUDING BY REQUESTING RECALL OF ALL COMPOUNDED TIRZEPATIDE COMBINED WITH UNTESTED ADDITIVES LIKE B12Further company coverage: LLY.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618041184","isCrawlerRequest":true}